Kosuke Shiki

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( <scp>EMPA‐ELDERLY</scp> )

Daisuke Yabe, Kosuke Shiki, Gosuke Homma et al. · Diabetes Obesity and Metabolism · 2023 · 70 citations · Full text

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui et al. · Diabetes Obesity and Metabolism · 2018 · 41 citations · Full text

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial

Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki et al. · Diabetes Obesity and Metabolism · 2018 · 40 citations · Full text

Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial

Hirohito Sone, Tatsuroh Kaneko, Kosuke Shiki et al. · Diabetes Obesity and Metabolism · 2019 · 28 citations · Full text

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

Daisuke Yabe, Kosuke Shiki, Keiko Suzaki et al. · BMJ Open · 2021 · 28 citations · Full text